SU‐E‐T‐85: A Systematic Analysis of Mono‐Isocentric Techniques for the Treatment of Multiple Metastasis
TL;DRAbstract
Purpose: In this planning study, we compared two mono‐isocentric techniques for the treatment of multiple brain metastasis. We hypothesize that, dynamic conformal arc delivery produces significantly more efficient plans of similar quality when compared to volumetric modulated arc therapy (VMAT). Methods: Recently published clinical data demonstrated a benefit in treating multiple brain metastasis (more than four mets) with SRS. A number of publications showed the feasibility of planning such patients with VMAT. In our study, we planned ten SRS patients with three to eight brain metastasis. The Varian eclipse system used four arcs with a VMAT optimized delivery whereas the Brainlab multiple elements software (MME) selected between 3 and 7 optimized arcs to deliver the prescribed dose using a hybrid conformal arc technique (non‐IMRT). Results: We have found that both planning systems achieved the goal to deliver the prescribed dose to the 99.5% of the tumor volume. The tumor doses ranged
Chat with Paper
AI Agents for this Paper
Purpose: In this planning study, we compared two mono‐isocentric techniques for the treatment of multiple brain metastasis. We hypothesize that, dynamic conformal arc delivery produces significantly more efficient plans of similar quality when compared to volumetric modulated arc therapy (VMAT). Methods: Recently published clinical data demonstrated a benefit in treating multiple brain metastasis (more than four mets) with SRS. A number of publications showed the feasibility of planning such patients with VMAT. In our study, we planned ten SRS patients with three to eight brain metastasis. The Varian eclipse system used four arcs with a VMAT optimized delivery whereas the Brainlab multiple elements software (MME) selected between 3 and 7 optimized arcs to deliver the prescribed dose using a hybrid conformal arc technique (non‐IMRT). Results: We have found that both planning systems achieved the goal to deliver the prescribed dose to the 99.5% of the tumor volume. The tumor doses ranged
Keywords
Chat
Click to start Chat